Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Diagnosing Liver Cancer Using Genetically Modified Probiotic Bacteria

By LabMedica International staff writers
Posted on 07 Jun 2015
A genetically engineered variety of the probiotic bacterium Escherichia coli Nissle 1917 was used to generate a luminescent diagnostic biomarker that could be detected in the urine of rodents with liver tumors.

Investigators at the Massachusetts Institute of Technology (Cambridge, MA, USA) and the University of California, San Diego (USA) genetically engineered E. More...
coli Nissle 1917 to carry the gene that encodes a lacZ reporter enzyme, which would normally cleave lactose into glucose and galactose. For the current study galactose linked-luciferin was provided as the substrate in test rodents, and the enzyme acted on this complex to produce free, luminescent luciferin, which was excreted and could be detected in the urine.

The investigators reported in the May 27, 2015, online edition of the journal Science Translational Medicine that E. coli Nissle 1917 robustly colonized tumor tissue in rodent models of liver metastasis after oral delivery but did not colonize healthy organs or fibrotic liver tissue. The microbial diagnostic generated a high-contrast urine signal through selective expansion in liver metastases (106-fold enrichment) and high expression of the lacZ reporter maintained by engineering a stable plasmid system. No deleterious health effects were detected in the mice more than 12 months after oral delivery.

The orally delivered bacteria did not accumulate in tumors all over the body, but did become established in nearly 90% of metastatic tumors in mice with colon cancer that had spread to the liver.

"We realized that if we gave a probiotic, we were not going to be able to get bacteria concentrations high enough to colonize the tumors all over the body, but we hypothesized that if we had tumors in the liver they would get the highest dose from an oral delivery," said senior author Dr. Sangeeta Bhatia, professor of health sciences, electrical engineering, and computer science, at the Massachusetts Institute of Technology. "There are interventions, like local surgery or local ablation, that physicians can perform if the spread of disease in the liver is confined, and because the liver can regenerate, these interventions are tolerated. New data are showing that those patients have a higher survival rate, so there is a particular need for detecting early metastasis in the liver."

Related Links:

Massachusetts Institute of Technology
University of California, San Diego



New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
All-in-One Molecular System
AIO M160
New
Benchtop Thermomixer
Biometra TS1 ThermoShaker
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Accurate immunotherapy selection for esophageal and GEJ carcinomas depends on consistent PD-L1 assessment (credit: Adobe Stock)

FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas

Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.